FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 740 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... April 9, 2026 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 Joining the dots: How our new research data strategy will unlock... July 7, 2022 10 Things Diet Soda Does to Your Body If You Drink... July 29, 2021 Load more HOT NEWS Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,...
